One-carbon Therapeutics AB announces the addition of multiple international experts to its Scientific Advisory Board
Professor Johann de Bono, Head of the Division of Clinical Studies and Drug Development Unit and Experimental Cancer Medicine at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, UK. Professor Timothy Yap, Vice President and Head of Clinical Development in the Therapeutics Discovery Division, The Institute for Applied Cancer Science MD […]
We will be in Copenhagen for the NLS days 29-30 November
We look forward to meeting you there!
Trick or trap by One Carbon Therapeutics
Read a short story of One-carbon Therapeutics achievements so far in Nature Biopharma Dealmakers (https://www.nature.com/articles/d43747-023-00079-z). We are working hard to bring our novel inhibitor into the clinic.
We are selected as the EIT Health’s Catapult 2022-2023 runner-up finalist
We look forward to showcasing our innovative approach targeting difficult to treat cancers at the 2023 Bits & Pretzels Healthtech event in Munich 20-21 June.
We are presenting exciting progress about MTHFD1/2 inhibitors at BIO International in Boston
You can listen to our company presentation on Monday, June 5 and during the 12th International Cancer Cluster Showcase satellite symposium at BIO.
One Carbon Therapeutics has been selected to present the MTHFD1/2 project to the International Board of MATWIN on May 10-11 th
We are excited to discuss our science and program with major pharma leaders.
Detailed mode of action of the MTHFD1/2 inhibitor TH9619 now published in Nature Metabolism
The One-carbon Therapeutics team is proud and excited to share our latest paper published inNature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitorTH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificityand emphasises the importance of utilising correct human-like conditions and cancer models in drugdevelopment. We show that cancer-specific […]
We are presenting our novel MTHFD1/2 inhibitor at the DDR inhibitor summit
We are presenting our data at the DDR inhibitor summit, January 24 – 26, 2023, Boston, USWe are excited to hear about the newest progress in the DDR field and look forward to all interestingdiscussions.
One-carbon therapeutics presents at Bio€quity 2022.
CEO Ana Slipicevic present the MTHFD2 program and one-carbon therapeutics AB in the Hot Topic session at Bio€quity 2022 in Milan.
MTHFD2 inhibitors now published in Nature Cancer
We are proud that the MTHFD2 inhibitors are now published in the prestigious journal Nature Cancer. In this first report, we describe that MTHFD2 inhibitors deplete cells of thymidine, specifically in cancer cells. We show that the loss of thymidine causes replication stress, which is a hallmark for DNA damage response (DDR) inhibitors and placing our […]
